PT987251E - 4-carboxiamino-2-metil-1,2,3,4-tetrahidroquinolinas como inibidores de cetp - Google Patents

4-carboxiamino-2-metil-1,2,3,4-tetrahidroquinolinas como inibidores de cetp

Info

Publication number
PT987251E
PT987251E PT99307264T PT99307264T PT987251E PT 987251 E PT987251 E PT 987251E PT 99307264 T PT99307264 T PT 99307264T PT 99307264 T PT99307264 T PT 99307264T PT 987251 E PT987251 E PT 987251E
Authority
PT
Portugal
Prior art keywords
cholesterol
inhibitors
levels
ldl
prodrug
Prior art date
Application number
PT99307264T
Other languages
English (en)
Inventor
Stephen Wayne Goldstein
Michael Raymond Makowski
Roger Benjamin Ruggeri
Ronald Thure Wester
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of PT987251E publication Critical patent/PT987251E/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/38—Nitrogen atoms
    • C07D215/42—Nitrogen atoms attached in position 4

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Diabetes (AREA)
  • Child & Adolescent Psychology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Quinoline Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
PT99307264T 1998-09-17 1999-09-14 4-carboxiamino-2-metil-1,2,3,4-tetrahidroquinolinas como inibidores de cetp PT987251E (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US10072998P 1998-09-17 1998-09-17

Publications (1)

Publication Number Publication Date
PT987251E true PT987251E (pt) 2004-10-29

Family

ID=22281233

Family Applications (1)

Application Number Title Priority Date Filing Date
PT99307264T PT987251E (pt) 1998-09-17 1999-09-14 4-carboxiamino-2-metil-1,2,3,4-tetrahidroquinolinas como inibidores de cetp

Country Status (10)

Country Link
US (2) US6140342A (pt)
EP (1) EP0987251B1 (pt)
JP (1) JP3626641B2 (pt)
AT (1) ATE267172T1 (pt)
BR (1) BR9904141A (pt)
CA (1) CA2282183C (pt)
DE (1) DE69917400T2 (pt)
DK (1) DK0987251T3 (pt)
ES (1) ES2220013T3 (pt)
PT (1) PT987251E (pt)

Families Citing this family (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6197786B1 (en) * 1998-09-17 2001-03-06 Pfizer Inc 4-Carboxyamino-2-substituted-1,2,3,4-tetrahydroquinolines
US6140342A (en) * 1998-09-17 2000-10-31 Pfizer Inc. Oxy substituted 4-carboxyamino-2-methyl-1,2,3,4-tetrahydroquinolines
US6147089A (en) * 1998-09-17 2000-11-14 Pfizer Inc. Annulated 4-carboxyamino-2-methyl-1,2,3,4,-tetrahydroquinolines
HN2000000203A (es) * 1999-11-30 2001-06-13 Pfizer Prod Inc Procedimiento para la obtencion de 1,2,3,4-tetrahidroquinolinas 4-carboxiamino-2- sustituidas.
DE10035352A1 (de) * 2000-07-20 2002-01-31 Zlb Bioplasma Ag Bern Verfahren zur Behandlung von instabiler Angina pectoris
US7115279B2 (en) 2000-08-03 2006-10-03 Curatolo William J Pharmaceutical compositions of cholesteryl ester transfer protein inhibitors
AU2001286243A1 (en) * 2000-09-14 2002-03-26 Kaken Pharmaceutical Co., Ltd. Tetrahydroquinoline compounds
DE10063486A1 (de) * 2000-12-20 2002-07-04 Bayer Ag Dichlorpyridylmethylamide
JP2005500314A (ja) * 2001-06-21 2005-01-06 ファイザー・プロダクツ・インク コレステロールエステル転送蛋白インヒビターの自己乳化性製剤
BR0210518A (pt) 2001-06-22 2004-06-22 Pfizer Prod Inc Composições farmacêuticas de dispersões de drogas e polìmeros neutros
EA006777B1 (ru) * 2001-06-22 2006-04-28 Пфайзер Продактс Инк. Фармацевтические композиции адсорбатов аморфного лекарственного средства
EP1269994A3 (en) 2001-06-22 2003-02-12 Pfizer Products Inc. Pharmaceutical compositions comprising drug and concentration-enhancing polymers
US7470659B2 (en) * 2001-12-07 2008-12-30 The Regents Of The University Of California Methods to increase reverse cholesterol transport in the retinal pigment epithelium (RPE) and Bruch's membrane (BM)
AR038375A1 (es) 2002-02-01 2005-01-12 Pfizer Prod Inc Composiciones farmaceuticas de inhibidores de la proteina de transferencia de esteres de colesterilo
EP1469832B2 (en) * 2002-02-01 2016-10-26 Bend Research, Inc. Pharmaceutical compositions of amorphous dispersions of drugs and lipophilic microphase-forming materials
BR0307332A (pt) * 2002-02-01 2004-12-07 Pfizer Prod Inc Formas de dosagem farmacêuticas de liberação controlada de um inibidor da proteìna de transferência do éster de colesterol
US20040053842A1 (en) * 2002-07-02 2004-03-18 Pfizer Inc. Methods of treatment with CETP inhibitors and antihypertensive agents
US7071210B2 (en) * 2002-07-02 2006-07-04 Pfizer Inc. CETP inhibitors in combination with antihypertensive agents and uses thereof
US7504508B2 (en) 2002-10-04 2009-03-17 Millennium Pharmaceuticals, Inc. PGD2 receptor antagonists for the treatment of inflammatory diseases
US20090181966A1 (en) * 2002-10-04 2009-07-16 Millennium Pharmaceuticals, Inc. PGD2 receptor antagonists for the treatment of inflammatory diseases
AU2003277285B2 (en) * 2002-10-04 2007-12-13 Millennium Pharmaceuticals, Inc. PGD2 receptor antagonists for the treatment of inflammatory diseases
EP1556356B1 (en) * 2002-10-21 2006-05-31 Warner-Lambert Company LLC Tetrahydroquinoline derivatives as crth2 antagonists
DE60331873D1 (de) 2002-12-20 2010-05-06 Pfizer Prod Inc Dosierungsform enthaltend einen CETP-Hemmer und einen HMG-CoA Reduktase Hemmer
US20040132771A1 (en) * 2002-12-20 2004-07-08 Pfizer Inc Compositions of choleseteryl ester transfer protein inhibitors and HMG-CoA reductase inhibitors
EP1435356A1 (en) * 2003-01-06 2004-07-07 Warner-Lambert Company LLC Quinoline derivatives as CRTH2 antagonists
US20040225018A1 (en) 2003-03-17 2004-11-11 Japan Tobacco Inc. Pharmaceutical compositions of CETP inhibitors
EP1603554A1 (en) * 2003-03-17 2005-12-14 Japan Tobacco Inc. Method for increasing the oral bioavailability of s-[2-([[1-(2-ethylbutyl)cyclohexyl]carbonyl]amino)phenyl]-2-methylpropanethioate
US20040204450A1 (en) * 2003-03-28 2004-10-14 Pfizer Inc Quinoline and quinoxaline compounds
TWI393560B (zh) * 2003-05-02 2013-04-21 Japan Tobacco Inc 包含ｓ-〔２（〔〔１-（２-乙基丁基）環己基〕羰基〕胺基）苯基〕２-甲基丙烷硫酯及ｈｍｇ輔酶ａ還原酶抑制劑之組合
CL2004001884A1 (es) 2003-08-04 2005-06-03 Pfizer Prod Inc Procedimiento de secado por pulverizacion para la formacion de dispersiones solidas amorfas de un farmaco y polimeros.
CA2532931A1 (en) * 2003-08-04 2005-02-10 Pfizer Products Inc. Pharmaceutical compositions of adsorbates of amorphous drugs and lipophilic microphase-forming materials
EP1670446A2 (en) 2003-09-26 2006-06-21 Japan Tobacco Inc. Method of inhibiting remnant lipoprotein production
US20050282812A1 (en) * 2004-06-18 2005-12-22 JONES Zachary Inhibitors of cholesteryl ester transfer protein
ES2407813T3 (es) 2004-08-04 2013-06-14 Meiji Seika Pharma Co., Ltd. Derivados de quinolina e insecticida que contienen los mismos como constituyente activo
US20060063803A1 (en) * 2004-09-23 2006-03-23 Pfizer Inc 4-Amino substituted-2-substituted-1,2,3,4-tetrahydroquinoline compounds
EP1844078B1 (en) 2005-02-03 2016-09-28 Bend Research, Inc Pharmaceutical compositions with enhanced performance
WO2006091674A1 (en) 2005-02-24 2006-08-31 Millennium Pharmaceuticals, Inc. Pgd2 receptor antagonists for the treatment of inflammatory diseases
US20060270675A1 (en) * 2005-03-10 2006-11-30 Groneberg Robert D Inhibitors of cholesterol ester transfer protein
WO2006098394A1 (ja) * 2005-03-14 2006-09-21 Japan Tobacco Inc. 脂質吸収抑制方法および脂質吸収抑制剤
US7678818B2 (en) * 2006-02-07 2010-03-16 Hoffmann-La Roche Inc. Anthranilamide and 2-amino-heteroarene-carboxamide compounds
CA2657258A1 (en) * 2006-07-20 2008-01-24 Novartis Ag Amino-piperidine derivatives as cetp inhibitors
NZ573439A (en) * 2006-07-20 2012-02-24 Novartis Ag Amino-piperidine derivatives as cetp inhibitors
PE20090982A1 (es) 2007-11-05 2009-08-13 Novartis Ag Derivados de piperidina como inhibidores de la proteina de transferencia de colesteril-ester (cetp)
US8759365B2 (en) 2007-12-03 2014-06-24 Novartis Ag Organic compounds
WO2009071099A1 (en) * 2007-12-05 2009-06-11 Aarhus Universitet Elevation of the plasma hdl-cholesterol level
GB0919431D0 (en) 2009-11-05 2009-12-23 Glaxosmithkline Llc Novel compounds
RS63143B1 (sr) 2016-06-01 2022-05-31 Athira Pharma Inc Jedinjenja
CN114853670B (zh) * 2022-05-23 2023-11-21 沈阳药科大学 含有酰胺基团的喹啉类化合物及其制备与应用

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5231102A (en) * 1989-03-08 1993-07-27 Merck Sharp & Dohme, Ltd. Tetrahydroquinoline derivatives useful for neurodegenerative disorders
US5276168A (en) * 1990-06-18 1994-01-04 E. R. Squibb & Sons, Inc. Benzopyran derivatives and heterocyclic analogs thereof as antiischemic agents
US5401848A (en) * 1990-11-26 1995-03-28 E. R. Squibb & Sons, Inc. Indane and quinoline derivatives
JPH0676403B2 (ja) * 1991-01-18 1994-09-28 エスエス製薬株式会社 新規なベンゾ［５，６ シクロヘプタ［１，２−ｂ ピリジン誘導体及びこれを含有する抗アレルギー剤
US5288725A (en) * 1992-10-15 1994-02-22 Merck & Co., Inc. Pyrroloquinoline Bradykinin antagonist
DE19627431A1 (de) 1996-07-08 1998-01-15 Bayer Ag Heterocyclisch kondensierte Pyridine
HRP970330B1 (en) * 1996-07-08 2004-06-30 Bayer Ag Cycloalkano pyridines
US6140342A (en) * 1998-09-17 2000-10-31 Pfizer Inc. Oxy substituted 4-carboxyamino-2-methyl-1,2,3,4-tetrahydroquinolines
AU2157400A (en) 1998-12-23 2000-07-31 G.D. Searle & Co. Combinations of cholesteryl ester transfer protein inhibitors and hmg coa reductase inhibitors for cardiovascular indications

Also Published As

Publication number Publication date
ES2220013T3 (es) 2004-12-01
CA2282183C (en) 2006-08-08
DE69917400T2 (de) 2005-05-19
JP2000191645A (ja) 2000-07-11
US6362198B1 (en) 2002-03-26
DK0987251T3 (da) 2004-09-27
EP0987251B1 (en) 2004-05-19
ATE267172T1 (de) 2004-06-15
DE69917400D1 (de) 2004-06-24
CA2282183A1 (en) 2000-03-17
JP3626641B2 (ja) 2005-03-09
EP0987251A1 (en) 2000-03-22
BR9904141A (pt) 2000-09-12
US6140342A (en) 2000-10-31

Similar Documents

Publication Publication Date Title
PT987251E (pt) 4-carboxiamino-2-metil-1,2,3,4-tetrahidroquinolinas como inibidores de cetp
UA70960C2 (uk) 4-амінозаміщені-2-заміщені-1,2,3,4-тетрагідрохіноліни як інгібітори протеїну, який переносить холестериловий етер
BR9904162A (pt) 4-carboxiamino-2-metil-1,2,3,4-tetra-hidroquinolinas aneladas
BG105428A (en) 4-carboxyamino-2-substituted-1,2,3,4-tetrahydroquinolines as cetp inhibitors
BR0114045A (pt) Poliarilcarboxamidas úteis como agentes redutores de lipìdeos
WO2002018324A3 (en) Immunoregulatory compounds, derivatives thereof and their use
MX9704671A (es) Esteres y amidas de acidos carboxilicos antiinflamatorios no esteroidales que pueden usarse como antioxidantes, inhibidores de 5-lipoxigenasa y productos antiiflamatorios no esteroidales.
WO2004085401A8 (en) 1,2,4-substituted 1,2,3,4-tetrahydro-and 1,2 dihydro-quinoline and 1,2,3,4-tetrahydro-quinoxaline derivatives as cetp inhibitors for the treatment of atherosclerosis and obesity
WO1999047497A3 (en) Carboxylic acids and acylsulfonamides, compositions containing such compounds and methods of treatment
ATE253545T1 (de) Biarylessigsäure-derivate und ihre verwendung als cox-2 inhibitoren
PT1004578E (pt) Derivados hidroxamida do acido 5-oxo-pirrolidino-2-carboxilico
DE60137399D1 (de) Propansäurederivate die die Bindung von Integrinen an ihre Rezeptoren hemmen
WO1997030677A3 (en) Pentafluorobenzenesulfonamides and analogs
AU6894800A (en) Caspase inhibitors and uses thereof
MXPA05012570A (es) Derivados de tetrahidroisoquinolina como activadores de ppar-a.
MX2007003441A (es) Compuestos de 4-amino-sustituido-2-sustituido-1,2,3,4- tetrahidroquinolina.
WO2001057021A3 (en) 2-[1H]-QUINOLONE AND 2-[1H]-QUINOXALONE INHIBITORS OF FACTOR Xa
PT1157998E (pt) Compostos heterociclicos seus intermediarios e inibidores da elastase
DE60002733D1 (de) Diester prodrugs von decahydroischinoline-3-carbonsäure
AU8998298A (en) Compounds having (2.2.1)bicyclo skeleton
DE60107832D1 (en) Chromenylmethylpyrimidindiamine als antibakterielle wirkstoffe
EA200101109A1 (ru) Производные 1-трифторметил-4-гидрокси-7-пиперидинил-аминометилхромана
EP1857444A1 (en) Tetrahydroisoquinoline compound and medicinal use thereof
AP2001002314A0 (en) Substituted benzolactam compounds.
AU2068895A (en) Dl- di- or tri-hydroxyphenylglycine alkyl esters for the treatment of inflammatory and allergic conditions